Trial Profile

A Phase III, multicentre, randomised trial comparing SARS-CoV-2 re-boost vaccine strategies in immunocompromised patients

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine adjuvanted Novavax (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics; Registrational
Acronyms OCTAVE DUO

09 Apr 2024 Planned End Date changed from 18 Apr 2023 to 20 Aug 2024.
09 Apr 2024 Status changed from completed to active, no longer recruiting.
26 Jun 2022 Results from data from the EASL COVID-Hep 2.0 registry, UK OCTAVE, OCTAVE DUO and PITCH studies reporting on Tcell and serological responses to a range of SARS-CoV-2 variants, 28-days after either two-doses (V2) of ChAdOx1 nCoV-19 or mRNA (mRNA-1273/BNT162b2) vaccination presented at The International Liver Congress 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com